arrow
L

Luis A. Quiñones

University of Chile
H指数:23
被引数:2,224

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CYP2C9 Pharmacogenetic Variants and Adverse Drug Reactions to Antiseizure Medications: An Exploratory Analysis in the Venezuelan Andes

CYP2C9药物基因组学变异和抗癫痫药物的不良药物反应:委内瑞拉安第斯山区的探索性分析

2026-09-290
OA
Association Between CYP2C9 and CYP2C19 Genetic Polymorphisms and Antiseizure Medication-Induced Adverse Reactions Among Peruvian Patients with Epilepsy

CYP2C9和CYP2C19基因多态性与秘鲁癫痫患者抗癫痫药物诱导不良反应之间的关联

2026-03-040
OAAI
Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial

优化铋剂四联疗法与标准克拉霉素为基础的三联疗法用于首次幽门螺杆菌根除的对比:一项双盲随机对照试验

2025-11-220
OAAI
Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer

影响智利晚期结直肠癌患者对5-氟尿嘧啶为基础治疗方案反应的遗传变异和临床决定因素

2025-08-020
OA
A pharmacogenetically-guided acenocoumarol dosing algorithm for Chilean patients: a discovery cohort study (vol 11,325,2020)

一种基于药物基因组学指导的醋硝香豆素给药剂量算法:一项针对智利患者的发现队列研究(卷11,325,2020)

2025-03-310
OA
Worldwide analysis of actionable genomic alterations in lung cancer and targeted pharmacogenomic strategies
HELIYON
IF3.6
2024-09-011
OAAI
Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries
2024-08-011
OAAI
Clinical and pulmonary function analysis in long-COVID revealed that long-term pulmonary dysfunction is associated with vascular inflammation pathways and metabolic syndrome

long-COVID的临床和肺功能分析显示,长期肺功能障碍与血管炎症途径和代谢综合征有关

2023-10-0612
OAAI
A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer
2021-09-168
OAAI